PROView

by GE Medical Systems SCS  · Based in United States → — AI-powered diagnostic software for comprehensive prostate MRI analysis and reporting.
Oncology Radiology Urology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for details
Regulatory Status Disclosed

Overview

PROView, developed by GE Medical Systems SCS (now part of GE HealthCare), is an advanced medical diagnostic software that leverages deep learning for the review, assessment, and reporting of multi-parametric prostate magnetic resonance (MR) images. It is explicitly designed to aid clinicians, radiologists, and physicians in following PI-RADS guidelines for prostate cancer assessment. This tool is not a physician directory.

The software provides a guided workflow for standardized assessment, including automated prostate segmentation, measurement of prostate and lesion volumes, and scoring of T2-weighted, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) acquisitions. It integrates patient clinical history, such as PSA levels, and automatically generates comprehensive reports with all measurements and selected images, which can be exported for seamless integration into external reporting solutions or PACS. PROView aims to deliver consistent quantification results and enhance the efficiency and accuracy of prostate MR exam interpretation and communication to referring physicians.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Deep learning-based automated prostate segmentation for consistent quantification results
  • Guided workflow for simple and standardized assessment of multi-parametric prostate MR series
  • Alignment with PI-RADSu00ae v2.1 guidelines for review, assessment, and reporting
  • Tools for prostate gland volume calculation and lesion analysis
  • Scoring of T2-weighted, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) acquisitions
  • Automated report generation with all measurements and selected images
  • Export reports in HTML, PDF, and DICOM for integration into external reporting solutions or PACS
  • Intelligent display of multi-parametric prostate MR series along with patient clinical history (e.g., PSA levels)
  • Facilitates communication of findings to referring physicians
  • Integration with ultrasound-based fusion systems for biopsy guidance

Use Cases

  • Review and assessment of multi-parametric prostate MR images
  • Aid in prostate cancer evaluation and diagnosis
  • Standardized reporting of prostate MRI findings according to PI-RADS guidelines
  • Support for treatment planning based on prostate lesion analysis
  • Enhancing consistency in prostate MRI interpretation across users
  • Exporting data for integration with ultrasound-based fusion systems for targeted biopsies

What Physicians Need to Know

Key Capabilities
PROView DL leverages deep learning for automated prostate segmentation, providing consistent quantification results. It offers a guided workflow for standardized assessment of multi-parametric prostate MR series, including intelligent display of MR images and patient PSA levels. The tool supports scoring of T2-weighted, DWI (with integrated ADC maps), and DCE acquisitions. It automates contouring and measurement of the prostate gland for volume and PSA density (PSAD) calculation, and includes dedicated tools for lesion localization and PI-RADSu00ae sector map reporting. Automated reports with measurements and images can be generated and exported.
Clinical Utility
PROView serves as an aiding tool for clinicians to review multi-parametric prostate MR images following PI-RADS guidelines, assisting in the assessment of prostate gland volume and analysis of findings in patients with known or suspected prostate lesions. It aims to standardize prostate reporting, fostering interdisciplinary agreement between urologists and radiologists for patient follow-up. The system helps determine PSA density, which is relevant to prostate size, and may contribute to reducing unnecessary biopsies and improving the accuracy of prostate cancer detection, particularly in identifying clinically significant cancers.
Integration Options
Reports generated by PROView can be exported into HTML for seamless integration into external reporting solutions, or saved as PDF and DICOM files to PACS. It integrates with standard dictation reporting systems. The software also allows segmented and measured MRI data to be exported to ultrasound-based fusion systems for targeted biopsies. PROView is available via AW, AW Server, and SIGNA Works Smart Subscription, and GE HealthCare generally supports open interfaces and interoperability for data sharing with other medical devices and information systems, including EHRs.
Compliance Status
PROView (specifically PROView DL) has received FDA 510(k) clearance (K193306) as a Class II medical diagnostic software. It is intended for use by healthcare professionals such as clinicians, radiologists, or physicians, with the understanding that the clinician retains ultimate responsibility for the final assessment and diagnosis. GE HealthCare maintains a comprehensive Compliance Program aligned with U.S. Department of Health and Human Services Office of Inspector General's guidance.
Pricing Model
PROView is offered through GE HealthCare's 'Smart Subscription' model, an application program designed to spread the cost of post-processing software over time. This subscription includes updates and upgrades for an annual fee per device and continues at the same price when compatible GE HealthCare MR systems are replaced. A minimum 3-year subscription is typically required.
User Experience
The system features a guided workflow for simple and standardized assessment, designed for speed and flexibility to integrate into existing clinical workflows. It offers easy mapping and scoring functionalities. The deep learning-based automated features aim to simplify tasks and deliver consistent results, with the goal of easing clinician workloads. PROView DL is described as 'extremely easy to use' and can be 'seamlessly incorporated into clinical practice without additional work for the radiologist'.
Support Quality
GE HealthCare provides customer support for equipment service and general inquiries. The company emphasizes a comprehensive Compliance Program that encourages reporting of concerns, and general feedback on GE Healthcare's customer support for other products has been positive.
Implementation Complexity
Implementation of GE HealthCare software and equipment is a collaborative effort between the customer and GE, guided by a Project Implementation Guide covering planning, installation, configuration, testing, and activation. Customers are responsible for ensuring timely availability of necessary infrastructure and allowing GE staff access. The Smart Subscription model aims to simplify deployment by creating a 'cloud-like environment within your facility's firewall' for seamless processing and data transfer. GE HealthCare acknowledges the inherent complexities of integrating advanced technologies across healthcare systems.
Evidence Base
PROView's deep learning algorithm for automatic prostate segmentation has been validated by GE HealthCare's engineering team using a database of MRI prostate exams, demonstrating that the algorithm meets acceptance criteria and improves performance on volume accuracy. The tool aligns with PI-RADSu00ae v2.1 reporting guidelines. Research indicates that MRI, which PROView supports, can improve accuracy in prostate cancer detection and potentially reduce unnecessary biopsies. GE HealthCare actively conducts AI research and verifies its AI tools with clinical experts.
Physician Tip

Leverage PROView's automated segmentation and PI-RADSu00ae v2.1 alignment for consistent and standardized prostate MRI reporting, which can enhance interdisciplinary communication and patient management. Utilize the integrated lesion localization and scoring tools to efficiently assess and report on suspicious findings. Consider integrating PROView's output with ultrasound-based fusion systems for more accurate targeted biopsies, potentially reducing the need for random biopsies and improving the detection of clinically significant prostate cancer. Remember that while the AI provides robust support, your clinical judgment remains paramount for final diagnosis and treatment planning.

PROView offers flexible integration pathways, including direct export to PACS via DICOM and compatibility with standard dictation reporting systems. Its ability to export data in HTML facilitates integration with various external reporting solutions. For advanced workflows, the software supports exporting segmented and measured MRI data to ultrasound-based fusion systems, streamlining targeted biopsy procedures. The Smart Subscription model, which hosts the application, is designed to operate within your facility's firewall, suggesting a secure and managed environment for data transfer and processing across your network.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact vendor for details
  • Subscription-based access through GE's Smart Subscription program; contact vendor for specific tiers and costs
DeploymentOn-premise (via GE provided server within facility's firewall, often through a Smart Subscription model)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Yes AI-estimated

PROView (K193306) is a Class II medical device, an image processing system for radiology, specifically cleared by the FDA on November 17, 2020. It is intended for use by clinicians, radiologists, or physicians to review multi-parametric prostate MR images following PI-RADS guidelines, aiding in the assessment of prostate gland volume and findings analysis in patients with known or suspected prostate lesions.
Integrations
EHR Not specified
Specialties Oncology, Radiology, Urology

What the Web Says

PROView by GE HealthCare is a prostate MR solution that utilizes deep learning for automated prostate segmentation, aiding in consistent volume measurement and aligning with PI-RADSu00ae v2.1 reporting. It offers a guided workflow for standardized assessment, including intelligent display of multi-parametric prostate MR series and patient clinical history. While some users praise its ease of use and comprehensive features, others express concerns about its cost and occasional performance issues.

Overall: Mixed

Strengths

  • Automated prostate segmentation using deep learning for consistent quantification.
  • Guided workflow for standardized assessment.
  • Dedicated tools for lesion localization and reporting on PI-RADS sector maps.
  • Improved internal communication and level of care in institutions.
  • User-friendly interface and ease of learning.
  • Robust billing features.

Limitations

  • Interface could be improved for a more contemporary feel.
  • Can be expensive, with additional costs for basic features or customization.
  • Can be slow and experience connectivity issues.
  • Lacks flexibility.
  • Does not provide real-time spell checks.
  • Difficulty in acquiring one-on-one customer support.

Based on reviews from: GE Healthcare (gehealthcare.com), Capterra, G2, Reddit, Indeed

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate PROView

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

GlobeNewswire
GE HealthCare Technologies Inc. (GEHC): 2025 Product Pipeline and Strategy Analysis Report
This report from October 2025 includes 'PROView 2.0' as part of GE HealthCare's product pipeline, described as a second-generation tomosynthesis unit. It provides extensive data on pipeline products, including development stage, regulatory path, and projected launch dates.
2025-10
GE Healthcare
Next chapter: cancer care with new tools and technologies - GE Healthcare
This article highlights GE HealthCare's Magnetic Resonance (MR) PROView as a tool for precision diagnosis in prostate cancer, offering a guided workflow for prostate volume calculation, PSA density, and lesion mapping. It utilizes PI-RADSu2122 v2.1 report guidelines to standardize MR evaluation.
unknown
GE Healthcare
The Future of Prostate Cancer Diagnosis Could Involve Fewer Biopsies - GE Healthcare
GE HealthCare has introduced software as part of its PROView prostate reporting package, enabling high-quality MRIs to be segmented, measured, and exported to ultrasound-based fusion systems. This aims to improve the accuracy of prostate cancer diagnosis and potentially reduce the need for biopsies.
unknown
GE HealthCare (Thailand)
PROView Body | GE HealthCare (Thailand)
PROView leverages deep learning for automated prostate segmentation, providing consistent quantification results and a guided workflow for standardized assessment of multi-parametric prostate MR series. It aligns with PI-RADSu00ae v2.1 reporting and includes tools for lesion localization and scoring.
unknown
AuntMinnie
GE products at RSNA 2020 include AI-enhanced imaging | AuntMinnie
At RSNA 2020, GE HealthCare showcased PROView DL, a reporting and scoring tool for prostate MR scans that conforms to PI-RADS version 2.1 standards and offers automated segmentation of the prostate. This was highlighted among other AI-enhanced imaging technologies.
2020-11
accessdata.fda.gov
PROView - Establishment Registration & Device Listing - FDA
This FDA listing confirms PROView as a Class II medical device, specifically a radiological image processing system, with the product code LLZ. It was cleared via 510(k) number K193306 on November 17, 2020.
2026-06
MDPI
Artificial Intelligence Based Algorithms for Prostate Cancer Classification and Detection on Magnetic Resonance Imaging: A Narrative Review - MDPI
This peer-reviewed article from May 2021 reviews AI algorithms for prostate cancer detection and classification, listing GE Medical Systems' PROView as an FDA 510(k) cleared product from November 2020, focusing on prostate segmentation and volumetry with AI-supported lesion segmentation.
2021-05
PMC
Computational healthcare: Present and future perspectives (Review) - PMC
This review article from December 2021 mentions GE Medical Systems' PROView as an AI-based application for diagnosis in radiology, cleared in 2020. It discusses the history and future prospects of AI in healthcare.
2021-12

Videos

Product demos, reviews, and walkthroughs for PROView.

View all on YouTube

Frequently Asked Questions

PROView, as a hypothetical AI tool, would aim to integrate seamlessly with existing Electronic Health Record (EHR) systems to support various clinical tasks. Its primary uses could include ambient clinical documentation, generating differential diagnoses, drafting assessment and plan notes, and providing real-time clinical insights during patient encounters.
For PROView to be compliant, it must adhere to strict HIPAA standards, including the Privacy Rule, Security Rule, and Breach Notification Rule, often requiring a Business Associate Agreement (BAA). This involves robust data encryption, access controls, and potentially a Zero-Trust Architecture to ensure the confidentiality, integrity, and availability of electronic Protected Health Information (ePHI).
Alternatives to PROView depend on its specific function; for clinical documentation, options include other AI scribes like Nuance DAX Copilot, Ambience, or Nabla, or traditional human medical scribes. For diagnostic support, physicians might rely on their clinical expertise, consultations with specialists, or other specialized AI diagnostic tools.
Pricing for healthcare AI solutions like PROView can vary widely, often involving subscription fees, usage-based models, or tiered compliance-based pricing. Factors influencing cost include the complexity of the AI model, the level of customization, integration requirements with existing systems, and ongoing maintenance and retraining needs.
Limitations of AI in clinical practice include potential biases from training data, a lack of generalizability to diverse patient populations, and the inability to convey empathy or fully replace human judgment. PROView would address these by maintaining a 'physician-in-the-loop' design, where the AI provides suggestions that a physician reviews and approves, and by continuous monitoring for model drift and bias.
PROView would ensure accuracy through rigorous training on extensive, high-quality medical datasets and continuous validation against clinical outcomes. For critical decisions, it would function as a clinical decision support tool, providing evidence-grounded suggestions that require physician oversight and final approval, rather than making autonomous decisions.
Effective adoption of PROView would necessitate comprehensive support and training, including onboarding programs, user manuals, and ongoing technical assistance. Vendors typically offer resources to help physicians understand the AI's capabilities, integrate it into their workflow, and address any operational questions.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from GE Medical Systems SCS

3DXR
GE Medical Systems SCS
Radiology & Imaging AI
3DXR is an AI-powered post-processing software by GE HealthCare that performs 3D reconstruction of X-ray interventional images, enhancing clarity by reducing artifacts for improved diagnosis and surgical planning.
Contact vendor
Bone VCAR (BVCAR)
GE Medical Systems SCS
Radiology & Imaging AI
Bone VCAR by GE Medical Systems SCS is an FDA-cleared, deep learning-based AI tool for automated CT spine analysis, designed to improve reading efficiency and reporting by providing automated spine labeling and reformat generation.
CardIQ Suite
GE Medical Systems SCS
Cardiology AI
CardIQ Suite is an AI-powered cardiac CT post-processing application by GE Medical Systems SCS, offering automated calcium scoring and CCTA review for comprehensive cardiovascular disease diagnosis and treatment planning.
Contact for pricing
FlightPlan for Embolization
GE Medical Systems SCS
Radiology & Imaging AI
FlightPlan for Embolization is an FDA-cleared AI-powered software by GE Medical Systems SCS that processes 3D X-ray angiography images to assist physicians in visualizing vasculature and planning embolization procedures.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.